| ATI-2341 CXCR4 allosteric agonist |
Sample solution is provided at 25 µL, 10mM.
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
Quality Control & MSDS
- View current batch:
-
Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
ATI-2341 Dilution Calculator
ATI-2341 Molarity Calculator
| Cas No. | 1337878-62-2 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S)-11-(4-aminobutyl)-14-((Z)-((2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S,21Z,23S,24Z,26S,27Z,30Z,32S,33Z)-17,20-bis(4-aminobutyl)-11-(3-guanidinopropyl)-1,4,7,10,13,16,19,22,25,28,31,34-dodecahydroxy-23-(3-hydroxy-3-iminop | ||
| Canonical SMILES | CCCCCCCCCCCCCCC/C(O)=N/[[email protected]@](/C(O)=N/C/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](/C(O)=N/[[email protected]@](C(O)=O)([H])CC(C)C)([ | ||
| Formula | C104H178N26O25S2 | M.Wt | 2256.82 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: 194 nM
ATI-2341 is a CXCR4 allosteric agonist.
Chemokine CXC-type receptor 4 (CXCR4) and its ligand CXCL12 mediate the retention of polymorphonuclear neutrophils and hematopoietic stem and progenitor cells in the bone marrow. Drugs disrupting CXCL12-mediated chemoattraction of CXCR4-expressing cells are useful for hematopoietic stem and progenitor cells (HSPCs) collection.
In vitro: ATI-2341 could inhibit NKH477-induced cAMP accumulation in CXCR4-HEK cells dose-dependently, but showed no effect in naive HEK-293 parental cells. Pretreatment of CXCR4- HEK cells with pertussis toxin completely abrogated the ability of ATI-2341 to inhibit cAMP accumulation. ATI-2341 could also induce a dose-dependent increase in intracellular calcium in cells transfected with wild-type CXCR4 whereas having no effect on untransfected cells. Activation of such signaling pathway by ATI-2341 was dependent on a fully functional CXCR4 receptor since ATI-2341 was not able to mobilize calcium in cells transfected with a CXCR4 receptor variant [1].
In vivo: ATI-2341 could induce dose-dependent peritoneal recruitment of polymorphonuclear neutrophils (PMNs) when i.p. administered to mice. However, when systemically administered by i.v. bolus, ATI-2341 acted as an antagonist and could dose-dependently mediate release of PMNs from the bone marrow of mice and cynomolgus monkeys. In addition, ATI-2341-mediated release of granulocyte/macrophage progenitor cells from the bone marrow was further confirmed by colony-forming assays [1].
Clinical trial: Up to now, ATI-2341 is still in the preclinical development stage.
Reference:
[1] Tchernychev B et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Natl Acad Sci U S A.2010 Dec 21;107(51):22255-9.